Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 4Phase 1 2Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 1

Conditions

Cushing Syndrome 2Pathologic Processes 1Neoplasms 1Hypertension 1Hyperglycemia 1Glucose Intolerance 1Endocrine System Diseases 1Diabetes Mellitus, Type 2 1Adrenocortical Hyperfunction 1Adrenocortical Carcinoma 1Adrenal Gland Diseases 1Adrenal Cortex Neoplasms 1ACTH Syndrome, Ectopic 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × relacorilant × Clear all
NCT04373265 2024-02-23

Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)

Corcept Therapeutics

Phase 1 Completed
15 enrolled
Endocrine

ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Adrenal Gland Diseases, Adrenocortical Hyperfunction, Cushing Syndrome, Diabetes Mellitus, Type 2, Endocrine System Diseases, Hyperglycemia, Hypertension, Pathologic Processes, Glucose Intolerance, Adrenocortical Carcinoma

NCT05347979 2023-02-09

Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants

Corcept Therapeutics

Phase 1 Completed
30 enrolled

Cushing Syndrome, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡